All In Biotech

Drug Trial Radar · NCT01091168

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

594

Actual

Start

Jul 2009

Primary completion

Aug 27, 2012

Study completion Jan 2014

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Mar 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.

Conditions

  • Breast Cancer
  • Metastases

Interventions

  • vinflunineDrug

    280 mg/m2 on day 1 of each cycle every 3 weeks

  • Alkylating agent of physician choice registered in cancerDrug

    cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From baseline up to 3 years 1 month

Locations

80 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Quilmes, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    San Martin, Argentina

  • Site not named

    San Miguel de Tucumán, Argentina

  • Site not named

    Graz, Austria

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Grodno, Belarus

  • Site not named

    Homyel, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Brussels, Belgium

  • Site not named

    Haine-Saint-Paul, Belgium

  • Site not named

    Yvoir, Belgium

  • Site not named

    Angers, France

  • Site not named

    Brest, France

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Dijon, France

  • Site not named

    Grenoble, France

  • Site not named

    Le Mans, France

  • Site not named

    Lille, France

  • Site not named

    Limoges, France

  • Site not named

    Lorient, France

  • Site not named

    Montpellier, France

  • Site not named

    Nancy, France

  • Site not named

    Nantes, France

  • Site not named

    Nice, France

  • Site not named

    Paris, France

  • Site not named

    Pontoise, France

  • Site not named

    Reims, France

  • Site not named

    Rouen, France

  • Site not named

    Saint-Brieuc, France

  • Site not named

    Saint-Priest-en-Jarez, France

  • Site not named

    Strasbourg, France

  • Site not named

    Berlin, Germany

  • Site not named

    Dortmund, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Munich, Germany

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.